Last reviewed · How we verify
Autologous mononuclear cells
At a glance
| Generic name | Autologous mononuclear cells |
|---|---|
| Sponsor | Timothy J Nelson, MD, PhD |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CAR- PRISM (PRecision Intervention Smoldering Myeloma) (PHASE2)
- UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 (PHASE1)
- CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies (PHASE1, PHASE2)
- Optimised CD33 (FL-33) CAR T Therapy for Refractory/Relapsed Acute Myeloid Leukaemia (PHASE1)
- Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma (PHASE1)
- REgulatory T Cell Therapy to Achieve Immunosuppression REduction (PHASE2)
- Hypofractionated Radiation in Combination With B7-H3-CAR T Cells for Pediatric Patients With Relapsed/Refractory Sarcomas (PHASE1)
- CardiAMP Heart Failure II Trial for Patients With Ischemic Heart Failure With Reduced Ejection Fraction (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous mononuclear cells CI brief — competitive landscape report
- Autologous mononuclear cells updates RSS · CI watch RSS
- Timothy J Nelson, MD, PhD portfolio CI